AiViva is developing drugs focused on multiple molecular targets that address neovascularization, abnormal cell proliferation, and fibrosis. We have used approved oral therapies with established human safety and efficacy and conducted robust nonclinical proof-of-concept studies. This approach enables us to pursue a risk-mitigated clinical development strategy. The active pharmaceutical ingredients in our lead products, AIV-001 and AIV-007, are multi-kinase inhibitors that exhibit multiple targeted effects including inhibition of VEGFR, FGFR, PDGFR, and/or TGF-β1 with preferential anti-angiogenic and anti-fibrotic activity. Our novel formulations of these compounds coupled with our proprietary JEL™ Technology are designed for focal treatment, optimized therapeutic effect and prolonged drug duration.
Our novel delivery method directly targets the treatment tissue and reduces systemic exposure, thus improving the benefit/risk profile compared with existing therapies. We are able to apply this treatment modality to a wide range of diseases in various therapeutic areas to capitalize on the benefits of our innovative technology for local drug delivery.